Duration of adrenal insufficiency during treatment for childhood acute lymphoblastic Leukemia

Journal of Pediatric Hematology/Oncology

Volumn 33, Issue 6, 2011, Pages 442-449

  Vestergaard, Therese Risom ^a   Juul, Anders ^b   Lausten Thomsen, Ulrik ^a   Lausen, Birgitte ^a   Hjalgrim, Henrik ^b   Kvist, Tine Kajsa ^b   Andersen, Elisabeth Wreford ^b   Schmiegelow, Kjeld ^a,c  

^a Rigshospitalet   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

acute lymphoblastic leukemia; adrenal insufficiency; cancer; childhood; hydrocortisone

Indexed keywords

ASPARAGINASE; CARMUSTINE; CORTICOTROPIN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; GLUCOCORTICOID; HYDROCORTISONE; HYDROXYUREA; MERCAPTOPURINE; METHOTREXATE; PREDNISOLONE; TETRACOSACTIDE; TIOGUANINE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADRENAL INSUFFICIENCY; ARTICLE; B CELL LEUKEMIA; CHILD; CHILDHOOD LEUKEMIA; CORTICOTROPIN TEST; DRUG WITHDRAWAL; ENDOCRINE FUNCTION TEST; FEMALE; HORMONE SUBSTITUTION; HUMAN; HYDROCORTISONE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; PRESCHOOL CHILD; PRIORITY JOURNAL; RISK FACTOR; SCHOOL CHILD; T CELL LEUKEMIA; TIME;

ADOLESCENT; ADRENAL INSUFFICIENCY; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; DEXAMETHASONE; FEMALE; HUMANS; HYDROCORTISONE; INFANT; INFECTION; MALE; PITUITARY-ADRENAL SYSTEM; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; TIME FACTORS;

EID: 80051707895     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e3182260cbe     Document Type: Article

References (43)

1. Byyny RL. Withdrawal from glucocorticoid therapy. N Engl J Med. 1976;295:30-32.
2. Lenore SL, Perrin CW. Adrenal Insufficiency. In: Kliegman RM, Behrman RE, Jenson HB, et al, eds. Nelson Textbook of Pediatrics. Philadelphia. Pensylvania: Elsevier Books, 2004.
3. Shulman DI, Palmert MR, Kemp SF. Adrenal insufficiency: Still a cause of morbidity and death in childhood. Pediatrics. 2007;119:484-494.
4. Miller WL. The adrenal cortex. In: Sperling MA, ed. Pediatric Endocrinology. United States of America: Saunders; 2002:385-438.
5. Gaynon PS, Lustig RH. The use of glucocorticoids in acute lymphoblastic leukemia of childhood. Molecular, cellular, and clinical considerations. J Pediatr Hematol Oncol. 1995;17:1-12.
6. Schmiegelow K, Heyman M, Gustafsson G, et al. The degree of myelosuppression during maintenance therapy of adolescents with B-lineage intermediate risk acute lymphoblastic leukemia predicts risk of relapse. Leukemia. 2010;24:715-720.
7. Wheeler K, Chessells JM, Bailey CC, et al. Treatment related deaths during induction and in first remission in acute lymphoblastic leukaemia: MRC UKALL X. Arch Dis Child. 1996;74:101-107. (Pubitemid 26057690)
8. Christensen MS, Heyman M, Mottonen M, et al. Treatmentrelated death in childhood acute lymphoblastic leukaemia in the Nordic countries: 1992 to 2001. Br J Haematol. 2005;131:50-58. (Pubitemid 43899707)
9. Lausen B, Schmiegelow K, Andreassen B, et al. Infections during induction therapy of childhood acute lymphoblastic leukaemia-no association to mannose-binding lectin deficiency. Eur J Haematol. 2006;76:481-487.
10. Christy NP. The clinical significance of pituitary-adrenal suppression by exogenous corticosteroids. J Chronic Dis. 1973;26:261-264.
11. Spiegel RJ, Vigersky RA, Oliff AI, et al. Adrenal suppression after short-term corticosteroid therapy. Lancet. 1979;1:630-633. (Pubitemid 9136910)
12. Rix M, Birkebaek NH, Rosthoj S, et al. Clinical impact of corticosteroid-induced adrenal suppression during treatment for acute lymphoblastic leukemia in children: A prospective observational study using the low-dose adrenocorticotropin test. J Pediatr. 2005;147:645-650. (Pubitemid 41598338)
13. Felner EI, Thompson MT, Ratliff AF, et al. Time course of recovery of adrenal function in children treated for leukemia. J Pediatr. 2000;137:21-24. (Pubitemid 30470917)
14. Lightner ES, Johnson H, Corrigan JJ Jr. Rapid adrenocortical recovery after short-term glucocorticoid therapy. Am J Dis Child. 1981;135:790-792. (Pubitemid 11018073)
15. Mahachoklertwattana P, Vilaiyuk S, Hongeng S, et al. Suppression of adrenal function in children with acute lymphoblastic leukemia following induction therapy with corticosteroid and other cytotoxic agents. J Pediatr. 2004;144:736-740. (Pubitemid 38858089)
16. Kuperman H, Damiani D, Chrousos GP, et al. Evaluation of the hypothalamic-pituitary-adrenal axis in children with leukemia before and after 6 weeks of high-dose glucocorticoid therapy. J Clin Endocrinol Metab. 2001;86:2993-2996. (Pubitemid 32673454)
17. Cunha CF, Silva IN, Finch FL. Early adrenocortical recovery after glucocorticoid therapy in children with leukemia. J Clin Endocrinol Metab. 2004;89:2797-2802. (Pubitemid 38766368)
18. Saracco P, Bertorello N, Farinasso L, et al. Steroid withdrawal syndrome during steroid tapering in childhood acute lymphoblastic leukemia: A controlled study comparing prednisone versus dexamethasone in induction phase. J Pediatr Hematol Oncol. 2005;27:141-144. (Pubitemid 40397243)
19. Petersen KB, Muller J, Rasmussen M, et al. Impaired adrenal function after glucocorticoid therapy in children with acute lymphoblastic leukemia. Med Pediatr Oncol. 2003;41:110-114. (Pubitemid 36858328)
20. Einaudi S, Bertorello N, Masera N, et al. Adrenal axis function after high-dose steroid therapy for childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2008;50:537-541. (Pubitemid 351155821)
21. Mitelman F. An International System for human Cytogenetic Nomenclature. Karger, S. 1995.
22. Czock D, Keller F, Rasche FM, et al. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet. 2005;44:61-98. (Pubitemid 40096038)
23. Chrousos GP. The stress response and immune function: Clinical implications. The 1999 Novera H. Spector Lecture. Ann N Y Acad Sci. 2000;917:38-67.
24. Menon K, Lawson M. Identification of adrenal insufficiency in pediatric critical illness. Pediatr Crit Care Med. 2007;8:276-278. (Pubitemid 46743740)
25. Klose M, Lange M, Rasmussen AK, et al. Factors influencing the adrenocorticotropin test: Role of contemporary cortisol assays, body composition, and oral contraceptive agents. J Clin Endocrinol Metab. 2007;92:1326-1333. (Pubitemid 46556405)
26. StataCorp.Stata Statistical Sorftwere.Version 11. College Station TSLP. 2009.
27. Schmiegelow K, Forestier E, Hellebostad M, et al. Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia. Leukemia. 2010;24:345-354.
28. Zollner EW. Hypothalamic-pituitary-adrenal axis suppression in asthmatic children on inhaled corticosteroids (Part 2)-the risk as determined by gold standard adrenal function tests: A systematic review. Pediatr Allergy Immunol. 2007;18:469-474. (Pubitemid 47206740)
29. Grinspoon SK, Biller BM. Clinical review 62: Laboratory assessment of adrenal insufficiency. J Clin Endocrinol Metab. 1994;79:923-931.
30. Gonc EN, Kandemir N, Kinik ST. Significance of low-dose and standard-dose ACTH tests compared to overnight metyrapone test in the diagnosis of adrenal insufficiency in childhood. Horm Res. 2003;60:191-197. (Pubitemid 37256066)
31. Agwu JC, Spoudeas H, Hindmarsh PC, et al. Tests of adrenal insufficiency. Arch Dis Child. 1999;80:330-333. (Pubitemid 29164755)
32. Dickstein G. The assessment of the hypothalamo-pituitaryadrenal axis in pituitary disease: Are there short cuts? J Endocrinol Invest. 2003;26:25-30.
33. Clayton RN. Diagnosis of adrenal insufficiency. BMJ. 1989; 298:271-272.
34. Shah A, Stanhope R, Matthew D. Hazards of pharmacological tests of growth hormone secretion in childhood. BMJ. 1992; 304:173-174.
35. Beale E, Zhu J, Belzberg H. Changes in serum cortisol with age in critically ill patients. Gerontology. 2002;48:84-92. (Pubitemid 34195724)
36. Abdu TA, Elhadd TA, Neary R, et al. Comparison of the low dose short synacthen test (1 microg), the conventional dose short synacthen test (250 microg), and the insulin tolerance test for assessment of the hypothalamo-pituitary-adrenal axis in patients with pituitary disease. J Clin Endocrinol Metab. 1999;84:838-843. (Pubitemid 29138205)
37. Gonzalbez J, Villabona C, Ramon J, et al. Establishment of reference values for standard dose short synacthen test (250 microgram), low dose short synacthen test (1 microgram) and insulin tolerance test for assessment of the hypothalamopituitary- adrenal axis in normal subjects. Clin Endocrinol (Oxf). 2000;53:199-204.
38. Weintrob N, Sprecher E, Josefsberg Z, et al. Standard and lowdose short adrenocorticotropin test compared with insulininduced hypoglycemia for assessment of the hypothalamicpituitary- adrenal axis in children with idiopathic multiple pituitary hormone deficiencies. J Clin Endocrinol Metab. 1998;83:88-92. (Pubitemid 28498315)
39. Moricke A, Reiter A, Zimmermann M, et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: Treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood. 2008;111:4477-4489.
40. Gaynon PS, Carrel AL. Glucocorticosteroid therapy in childhood acute lymphoblastic leukemia. Adv Exp Med Biol. 1999;457:593-605. (Pubitemid 129735357)
41. Yang JJ, Bhojwani D, Yang W, et al. Genome-wide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia. Blood. 2008;112:4178-4183.
42. Schmiegelow K, Vestergaard T, Nielsen SM, et al. Etiology of common childhood acute lymphoblastic leukemia: The adrenal hypothesis. Leukemia. 2008;22:2137-2141.
43. Greaves M. Molecular genetics, natural history and the demise of childhood leukaemia. Eur J Cancer. 1999;35:173-185. (Pubitemid 29136764)